source
- Roche's KRAS inhibitor divarasib shows strong results in second-line lung cancer trial at ESMORoche presented data from a trial of its KRAS G12C inhibitor divarasib at the European Society for Medical Oncology meeting. The study evaluated divarasib in patients with advanced non-small cell…
- Moderna and Merck aim to file personalized cancer vaccine for FDA approval after Phase 3 successModerna CEO Stéphane Bancel said the company’s personalized cancer vaccine, intismeran, met its primary goals in a pivotal Phase 3 trial. The success was disclosed during an interview at the ESMO m…